Literature DB >> 25386833

Recent advances in cell replacement therapies for the treatment of type 1 diabetes.

Kathryn Cogger1, Maria Cristina Nostro.   

Abstract

Exogenous insulin administration is currently the only treatment available to all type 1 diabetes patients, but it is not a cure. By helping to regulate circulating blood glucose levels, it has significantly improved life expectancy, but there are still long-term complications associated with the disease that may be preventable with a treatment strategy that can provide better glycemic control. Isolated islet (or whole pancreas) transplantation, xenotransplantation, and the transplant of human pluripotent stem cell-derived β-cells provide the potential to restore endogenous insulin production and reestablish normoglycemia. Here, we discuss the latest advances in these fields, including the use of encapsulation technology, as well as some of the hurdles that still need to be overcome for these alternative therapies to become mainstream and/or progress to clinical development.

Entities:  

Mesh:

Year:  2015        PMID: 25386833     DOI: 10.1210/en.2014-1691

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Patient and family expectations of beta-cell replacement therapies in type 1 diabetes.

Authors:  Akitsu Kawabe; Shinichi Matsumoto; Masayuki Shimoda
Journal:  Islets       Date:  2018-08-17       Impact factor: 2.694

2.  Injectable Polyethylene Glycol Hydrogel for Islet Encapsulation: an in vitro and in vivo Characterization.

Authors:  Tracy Knobeloch; Sakineh Esmaeili Mohsen Abadi; Joseph Bruns; Silviya Petrova Zustiak; Guim Kwon
Journal:  Biomed Phys Eng Express       Date:  2017-06-14

3.  Efficient Differentiation of Pluripotent Stem Cells to NKX6-1+ Pancreatic Progenitors.

Authors:  Emily C McGaugh; M Cristina Nostro
Journal:  J Vis Exp       Date:  2017-03-07       Impact factor: 1.355

Review 4.  Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style.

Authors:  Allyson J Merrell; Ben Z Stanger
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03-16       Impact factor: 94.444

5.  Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets.

Authors:  Jeffrey M H Liu; Jesse Zhang; Xiaomin Zhang; Kelan A Hlavaty; Christine F Ricci; Joshua N Leonard; Lonnie D Shea; R Michael Gower
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

Review 6.  Direct Lineage Reprogramming: Harnessing Cell Plasticity between Liver and Pancreas.

Authors:  Silvia Ruzittu; David Willnow; Francesca M Spagnoli
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-07-01       Impact factor: 9.708

Review 7.  New directions for the treatment of adrenal insufficiency.

Authors:  Gerard Ruiz-Babot; Irene Hadjidemetriou; Peter James King; Leonardo Guasti
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-06       Impact factor: 5.555

8.  Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors.

Authors:  Kathryn F Cogger; Ankit Sinha; Farida Sarangi; Emily C McGaugh; Diane Saunders; Craig Dorrell; Salvador Mejia-Guerrero; Yasaman Aghazadeh; Jillian L Rourke; Robert A Screaton; Markus Grompe; Philip R Streeter; Alvin C Powers; Marcela Brissova; Thomas Kislinger; M Cristina Nostro
Journal:  Nat Commun       Date:  2017-08-24       Impact factor: 14.919

Review 9.  Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations.

Authors:  Jacob A Tatum; Max O Meneveau; Kenneth L Brayman
Journal:  Diabetes Metab Syndr Obes       Date:  2017-02-28       Impact factor: 3.168

Review 10.  Genome-edited human stem cell-derived beta cells: a powerful tool for drilling down on type 2 diabetes GWAS biology.

Authors:  Nicola L Beer; Anna L Gloyn
Journal:  F1000Res       Date:  2016-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.